2022 World Conference on Lung Cancer (ePosters)-EP08.02-095. Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib

EP08.02-095. Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib

Back to course

Pdf Summary

This case study reports on the successful treatment of a stage IVB non-small cell lung cancer (NSCLC) patient with multiple genetic mutations using the drug aumolertinib. The patient, a 53-year-old female, was initially diagnosed with left upper lobe adenocarcinoma and had a combination of EGFR exon 19 deletion, TP53, and ERBB2 20ins mutations.<br /><br />The patient was initially treated with gefitinib as a first-line treatment but developed multiple new metastatic lesions in both lungs. Genetic testing confirmed the presence of the aforementioned mutations. The patient then received aumolertinib as a second-line treatment, which initially showed a positive response with the primary tumor and lung metastases shrinking. However, after four months, the primary lesion increased, and lymph node metastases appeared.<br /><br />The patient then underwent a combination treatment of aumolertinib and bevacizumab, which resulted in stable disease. This treatment plan was continued for seven months, and further evaluation showed no progression. The patient continued to take the combination treatment, and as of the report, her overall survival has exceeded 29 months.<br /><br />Throughout the treatment, the patient experienced mild adverse events, including dysgeusia, hepatotoxicity, epistaxis, and hypertension, which were manageable and mostly grade 1.<br /><br />This case study highlights the successful use of aumolertinib in a complex mutation background in NSCLC patients. It suggests that aumolertinib may provide a promising treatment option for patients with EGFR-sensitive mutations combined with other genetic mutations, potentially extending their survival. Further research and studies are needed to validate these findings and explore the efficacy of aumolertinib in similar patient populations.

Asset Subtitle

Chunling Liu

Meta Tag

Speaker Chunling Liu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

stage IVB non-small cell lung cancer

NSCLC

genetic mutations

aumolertinib

EGFR exon 19 deletion

metastatic lesions

lymph node metastases

bevacizumab

stable disease

survival